The aim of this study was to confirm the efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) in reducing clinical respiratory signs and the number of concomitant treatments under field conditions.
Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions
Live vaccine against Bovine Respiratory Syncytial Virus (BRSV), in suspension for injection or nasal spray for cattle.
Inactivated vaccine against pneumonia caused by Histophilus somni and Mannheimia haemolytica leukotoxoid, in injectable emulsion.
Live vaccine (double gene deleted gE-/tk-) against IBR virus, in injectable freeze-dried tablet
Inactivated vaccine against infectious bovine keratoconjunctivitis, in injectable suspension
Inactivated vaccine against enterotoxaemia, tetanus and blackleg, in injectable suspension
Inactivated vaccine against enterotoxaemia, sudden death, blackleg and black disease, in injectable suspension
Inactivated vaccine against IBR (1.5), BVD (1.2) and bovine leptospirosis, in injectable emulsion
An innovative service based on data analysis that facilitates decision-making in Cattle
This online calculator will allow you to know your farm costs, find out the costs associated with clinical and subclinical mastitis and analyse the production losses associated with mastitis
HIPRA University offers high quality training programmes in strategic areas of interest for professionals
Discover HIPRA’s pioneer programme to rear animals without the use of preventive antibiotics or coccidiostats
HIPRA has specially developed several online tools to support veterinarians and other Animal Health professionals in their daily work.
Discover our latest news